Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06684522 · ClinicalTrials.gov registry record · Early Phase 1
Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis
A Early Phase 1 study, sponsored by Northwestern University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT06684522 is a Early Phase 1 study that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 10 participants.
The verdict
NCT06684522, a Early Phase 1 study, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.
Interventions
- DRUG Upadacitinib 15 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-12-18 |
| Est. Completion | 2027-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06684522
The ClinicalTrials.gov registry entry for NCT06684522 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Upadacitinib 15 MG is the first listed.
NCT06684522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06684522 about?
NCT06684522 is a clinical study titled "Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis". This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.
What is the current status of trial NCT06684522?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2025-12-18. Estimated completion is 2027-06.
What interventions are being tested in trial NCT06684522?
The interventions under investigation include: Upadacitinib 15 MG (DRUG).
Who is sponsoring clinical trial NCT06684522?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.